van der Laan M - Search Results

1

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.

Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, Kabami J, Sang N, Liegler T, Chamie G, Camlin CS, Jain V, Kadede K, Atukunda M, Ruel T, Shade SB, Ssemmondo E, Byonanebye DM, Mwangwa F, Owaraganise A, Olilo W, Black D, Snyman K, Burger R, Getahun M, Achando J, Awuonda B, Nakato H, Kironde J, Okiror S, Thirumurthy H, Koss C, Brown L, Marquez C, Schwab J, Lavoy G, Plenty A, Mugoma Wafula E, Omanya P, Chen YH, Rooney JF, Bacon M, van der Laan M, Cohen CR, Bukusi E, Kamya MR, Petersen M. Havlir DV, et al. Among authors: van der laan m. N Engl J Med. 2019 Jul 18;381(3):219-229. doi: 10.1056/NEJMoa1809866. N Engl J Med. 2019. PMID: 31314966 Free PMC article. Clinical Trial.

2

Estimation of direct causal effects.

Petersen ML, Sinisi SE, van der Laan MJ. Petersen ML, et al. Epidemiology. 2006 May;17(3):276-84. doi: 10.1097/01.ede.0000208475.99429.2d. Epidemiology. 2006. PMID: 16617276

3

Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials.

Petersen ML, Wang Y, van der Laan MJ, Bangsberg DR. Petersen ML, et al. J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S96-S103. doi: 10.1097/01.qai.0000248344.95135.8d. J Acquir Immune Defic Syndr. 2006. PMID: 17133209

4

Super learning: an application to the prediction of HIV-1 drug resistance.

Sinisi SE, Polley EC, Petersen ML, Rhee SY, van der Laan MJ. Sinisi SE, et al. Stat Appl Genet Mol Biol. 2007;6:Article7. doi: 10.2202/1544-6115.1240. Epub 2007 Feb 23. Stat Appl Genet Mol Biol. 2007. PMID: 17402922 Free PMC article.

5

Individualized treatment rules: generating candidate clinical trials.

Petersen ML, Deeks SG, van der Laan MJ. Petersen ML, et al. Stat Med. 2007 Nov 10;26(25):4578-601. doi: 10.1002/sim.2888. Stat Med. 2007. PMID: 17450501 Free PMC article.

6

Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.

Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, Fessel WJ. Petersen ML, et al. AIDS. 2007 Jul 31;21(12):1547-54. doi: 10.1097/QAD.0b013e32825a69a8. AIDS. 2007. PMID: 17630549 Free PMC article.

7

Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis.

Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Petersen ML, et al. Clin Infect Dis. 2007 Oct 1;45(7):908-15. doi: 10.1086/521250. Epub 2007 Aug 20. Clin Infect Dis. 2007. PMID: 17806060 Free PMC article.

8

History-adjusted marginal structural models for estimating time-varying effect modification.

Petersen ML, Deeks SG, Martin JN, van der Laan MJ. Petersen ML, et al. Am J Epidemiol. 2007 Nov 1;166(9):985-93. doi: 10.1093/aje/kwm232. Epub 2007 Sep 17. Am J Epidemiol. 2007. PMID: 17875580 Free PMC article.

9

Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection.

Bembom O, Petersen ML, Rhee SY, Fessel WJ, Sinisi SE, Shafer RW, van der Laan MJ. Bembom O, et al. Stat Med. 2009 Jan 15;28(1):152-72. doi: 10.1002/sim.3414. Stat Med. 2009. PMID: 18825650 Free PMC article.

10

Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.

Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Petersen ML, et al. AIDS. 2008 Oct 18;22(16):2097-106. doi: 10.1097/QAD.0b013e32830f97e2. AIDS. 2008. PMID: 18832873 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

514 results

Search Page

Filters